SCHEMBL14176751

SCHEMBL14176751

CC(C)NC(=O)c1ccccc1-c1c2ccc(=[N+](C)C)cc-2oc2cc(N(C)C)ccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.61
▸ THRB P10828 1/20 0.61
▸ RECQL P46063 1/20 0.61
▸ BLM P54132 1/20 0.61
▸ KMT2A Q03164 1/20 0.61
▸ TDP1 Q9NUW8 1/20 0.61
▸ P2RY6 Q15077 1/20 0.57
▸ CA12 O43570 3/20 0.47
▸ CA1 P00915 3/20 0.47
▸ CA2 P00918 3/20 0.47
▸ CA9 Q16790 3/20 0.47
▸ ITPR1 Q14643 1/20 0.47
▸ FPR2 P25090 4/20 0.45
▸ ABCB1 P08183 1/20 0.44
▸ P2RY2 P41231 1/20 0.44
▸ USP2 O75604 1/20 0.42
▸ CFTR P13569 1/20 0.42
▸ PAX8 Q06710 1/20 0.42
▸ ATM Q13315 1/20 0.42
▸ GOPC Q9HD26 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14399388 0.90 MEN1 (0.64) MEN1THRBRECQLBLMKMT2A
Rhodamine Ii SCHEMBL30320900 0.88 MEN1 (0.64) MEN1THRBRECQLBLMKMT2A
Rhodamine Ii SCHEMBL12310066 0.88 MEN1 (0.64) MEN1THRBRECQLBLMKMT2A
SCHEMBL17702684 0.86 P2RY6 (0.64) MEN1THRBRECQLBLMKMT2A
Tetramethylrhodamine SCHEMBL2054818 0.86 MEN1 (0.71) MEN1THRBRECQLBLMKMT2A
SCHEMBL19767480 0.86 P2RY6 (0.75) MEN1THRBRECQLBLMKMT2A
SCHEMBL14399201 0.85 MEN1 (0.67) MEN1THRBRECQLBLMKMT2A
Tetramethylrhodamine SCHEMBL29838750 0.85 P2RY6 (0.67) MEN1THRBRECQLBLMKMT2A
Tetramethylrhodamine SCHEMBL13815486 0.85 P2RY6 (0.67) MEN1THRBRECQLBLMKMT2A
Tetramethylrhodamine SCHEMBL29587824 0.85 P2RY6 (0.66) MEN1THRBRECQLBLMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080138817-A1 Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same CREDIA JAPAN CO., LTD. (JP) 2008-06-12 — — US disclosed
US-20080138817-A1 Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same CREDIA JAPAN CO., LTD. (JP) 2008-06-12 — — US disclosed
US-7282575-B2 Functional peptide nucleic acid monomer and process for producing the same CREDIA JAPAN CO., LTD. (JP) 2007-10-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080138817-A1 Novel Functional Peptide Nucleic Acid Monomer and Process for Producing the Same NSUN3, RNGTT, NSUN2 MEN1 3066/4885THRB 304/4885RECQL 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback